Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: A 6-year prospective candidaemia survey from the fungal infection network of Switzerland

Clinical Microbiology and Infection

Volumn 20, Issue 7, 2014, Pages 698-705

  Orasch, C ^a   Marchetti, O ^a   Garbino, J ^b   Schrenzel, J ^b   Zimmerli, S ^c   Muhlethaler K ^c   Pfyffer, G ^d   Ruef, C ^e   Fehr, J ^e   Zbinden, R ^f   Calandra, T ^a   Bille, J ^a   Bregenzer, Thomas ^g   Conen, Anna ^g   Fankhauser, Hans ^g   Flückiger, Ursula ^h   Khanna, Nina ^h   Frei, Reno ^h   Heininger, Ulrich ⁱ   Hertel, Roland ⁱ   Franciolli, Mario ^j   Giovanni, Ospedale San ^j   Dolina, Marisa ^k   Rothen, Madeleine ^l   Dubuis, Olivier ^m   Tarr, Philipp ⁿ   Graf, Suzanne ^n,r   Fleisch, Felix ⁿ   Risch, Martin ⁿ   Ritzler, Eva ⁿ   Chuard, Christian ^o   Erard, Veronique ^o   Fracheboud, Dominique ^o   Emonet, St́ephane ^b   Genne, Daniel ^p   Lienhardt, Reto ^p   Chave, Jean Philippe ^q   Andreutti Zaugg, Corinne ^q   Gallusser, Alberto ^q   Graber, Peter ^r   Monotti, Rita ^s   Regionale, Ospedale ^s   Bernasconi, Enos ^t   Civico, Ospedale ^t   Krause, Martin ⁿ   Herzog, Karin ⁿ   Piso, Rein Jan ⁿ   Schibli, Urs ⁿ   Bally, Frank ^u   Troillet, Nicolas ^u   Tissiére, Lysiane ^u   Boggian, Katja ⁿ   Bruderer, Thomas ⁿ   Gubler, Jacques ^v   Eich, Gerhard ^w   Berger, Christoph ^x   more..

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d LUZERNER KANTONSSPITAL   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g CANTONAL HOSPITAL AARAU   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ Universitatskinderspital   (Switzerland)

^j OSPEDALE SAN GIOVANNI   (Switzerland)

^k Istituto Cantonale di Microbiologia   (Switzerland)

^l Spitalzentrum Biel   (Switzerland)

^m Viollier Microbiology Laboratories   (Switzerland)

ⁿ KANTONSSPITAL   (Switzerland)

^o Hopital Cantonal de Fribourg   (Switzerland)

^p Hopital Communal   (Switzerland)

^q Laboratory of Clinique de La Source   (Switzerland)

^r Kantonsspital Liestal   (Switzerland)

^s Ospedale Regionale Locarno   (Switzerland)

^t Ospedale Civico Lugano   (Switzerland)

^u Institut Central des Hopitaux Valaisans   (Switzerland)

^v CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

^w TRIEMLI HOSPITAL   (Switzerland)

^x Universitatskinderspital   (Switzerland)

more..

Author keywords

Breakpoint; Candida; Candidaemia; Clinical and laboratory standards institute; European committee on antimicrobial susceptibility testing; Resistance; Species

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CONTROLLED STUDY; CROSS RESISTANCE; FUNGUS ISOLATION; HEALTH SURVEY; IN VITRO STUDY; LABORATORY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPECIES DISTRIBUTION; STANDARD; SWITZERLAND; CLASSIFICATION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; SWITZERLAND; VORICONAZOLE;

EID: 84904872288     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12440     Document Type: Article

References (30)

1. Marchetti O, Bille J, Fluckiger U et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-320.
2. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-1239.
3. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-1377.
4. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 2011; 55: 561-566.
5. Sampaio Camargo TZ, Marra AR, Silva CV et al. Secular trends of candidemia in a tertiary care hospital. Am J Infect Control 2010; 38: 546-551.
6. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180-195.
7. Pfaller MA, Andes D, Arendrup MC et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70: 330-343.
8. Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-176.
9. Warren HBHK. Candida, Cryptococcus, and other yeasts of medical importance. In: Murray PR, ed. Manual of Clinical Microbiology. Washington DC: ASM Press, 2008; 1184-1199.
10. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, in Approved standard M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008a.
11. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, in 3rd informal Supplement, M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008b.
12. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth International Supplement. CLSI document M27-4. Wayne, PA: Clinical and Laboratory Standards Institute, 2012; 32.
13. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-1177.
14. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002; 50: 56-65.
15. Poikonen E, Lyytikainen O, Anttila VJ et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010; 10: 312.
16. Cuesta I, Bielza C, Larranaga P et al. Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2009; 53: 2949-2954.
17. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-447.
18. Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007; 51: 3599-3604.
19. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20: 391-408, table of contents.
20. Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005; 43: 4434-4440.
21. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 2011; 38: 65-69.
22. Rodriguez-Hernandez MJ, Ruiz-Perez de Pipaon M, Marquez-Solero M et al. [Candidemias: multicentre analysis in 16 hospitals in Andalusia (Spain)]. Enferm Infecc Microbiol Clin 2011; 29: 328-333.
23. Chalmers C, Gaur S, Chew J et al. Epidemiology and management of candidaemia-a retrospective, multicentre study in five hospitals in the UK. Mycoses 2011; 54: e795-e800.
24. Jung SI, Shin JH, Song JH et al. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med Mycol 2010; 48: 669-674.
25. Gonzalez GM, Elizondo M, Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J Clin Microbiol 2008; 46: 2902-2905.
26. Lyon GM, Karatela S, Sunay S, Adiri Y. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol 2010; 48: 1270-1275.
27. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
28. Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011; 49: 325-334.
29. Schmalreck AF, Willinger B, Haase G et al. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study. Mycoses 2012; 55: e124-e137.
30. Peman J, Canton E, Quindos G et al. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother 2012; 67: 1181-1187.